Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 63Breast Neoplasms 28Neoplasms 5Neoplasm Metastasis 3Leiomyoma 3Cardiovascular Diseases 3Polycystic Ovary Syndrome 2Neoplasms by Site 2Endometrial Neoplasms 2Breast Diseases 2Advanced Breast Cancer 2Stage II Prostate Adenocarcinoma 1Sleep Wake Disorders 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sarcopenia 1Salivary Gland Neoplasms 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms, Castration-Resistant 1Prostatectomy 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Pelvic Pain 1Ovarian Neoplasms 1Osteoporosis 1Oligometastatic Prostate Carcinoma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Metastatic Neuroendocrine Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 2prednylidene 1gallium 68 PSMA-11 1deltacortene 1apalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stage II Prostate Adenocarcinoma × Gonadotropin-Releasing Hormone × Clear all
NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡